Check out our latest podcast episode on global oil & gas investments. Watch now!
Sales & Support: +1 800 762 3361
Member Resources
Industrial Info Resources Logo
Global Market Intelligence Constantly Updated Your Trusted Data Source for Industrial & Energy Market Intelligence
Home Page

Advanced Search


Released December 29, 2021 | BEIJING
en
Researched by Industrial Info Resources (Sugar Land, Texas)--China's carbon neutrality and emissions policy has had an impact on a few of the country's chemical synthetic pharmaceutical plants, but that hasn't stopped plans for new projects.

Industrial Info is tracking 78 active capital pharmaceutical intermediates projects in China, with a combined investment value of more than US$300 billion. This includes 26 projects under construction, worth $1.02 billion, and 46 projects, worth $1.88 billion, that are planned to kick off construction in 2022. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of detailed project reports.

Anhui Jinquan Biotechnology Company Limited has more than US$164.9 million in planned projects. It is followed by Henan Weiyuan Biotechnology Company Limited and Huangshi Fertai Pharmaceutical Tech Company Limited.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.

IIR Logo Globe

Site-wide Scheduled Maintenance for September 27, 2025 from 12 P.M. to 6 P.M. CDT. Expect intermittent web site availability during this time period.

×
×

Contact Us

For More Info!